MLL-TFE3: a novel and aggressive KMT2A fusion identified in infant leukemia

    Thumbnail
    Citations
    Altmetric
    Author
    Kosasih, HJ; Davidson, NM; Bjelosevic, S; Morrish, E; Brennan, MS; Oshlack, A; Johnstone, RW; Brumatti, G; Khaw, SL; Ekert, PG
    Date
    2020-10-13
    Source Title
    Blood Advances
    Publisher
    AMER SOC HEMATOLOGY
    University of Melbourne Author/s
    Khaw, Seong; Johnstone, Ricky; Brumatti, Gabriela; Oshlack, Alicia; Ekert, Paul; Bjelosevic, Stefan; Morrish, Emma; Davidson, Nadia
    Affiliation
    Medical Biology (W.E.H.I.)
    Microbiology and Immunology
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Kosasih, H. J., Davidson, N. M., Bjelosevic, S., Morrish, E., Brennan, M. S., Oshlack, A., Johnstone, R. W., Brumatti, G., Khaw, S. L. & Ekert, P. G. (2020). MLL-TFE3: a novel and aggressive KMT2A fusion identified in infant leukemia. BLOOD ADVANCES, 4 (19), pp.4918-4923. https://doi.org/10.1182/bloodadvances.2020002708.
    Access Status
    Access this item via the Open Access location
    URI
    http://hdl.handle.net/11343/254260
    DOI
    10.1182/bloodadvances.2020002708
    Open Access URL
    Published version
    NHMRC Grant code
    NHMRC/1140626
    Abstract
    Key Points A novel KMT2A-rearrangement, MLL-TFE3, was identified in an infant leukemia patient. MLL-TFE3 expression produces aggressive leukemia in a mouse model.

    Export Reference in RIS Format     

    Collections